The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...
Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...
Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...
Second primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic ...
Fourteen Hispanic individuals who underwent comprehensive analysis were identified to carry a mutation in BRCA1 or BRCA2 (17.9%; 95% CI, 10.2% to 28.3%) and seven individuals had a variant of ...
Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy Conclusion: In a clinical setting, we show a high demand ...
Testing to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and factors ...
Researchers have understood for decades the importance that DNA repair mechanisms play in maintaining genomic integrity and keeping carcinogenesis in check. For instance, the BRACA1/2 genes and ...
Among the 124 undergoing germline testing based on high risk, their average age was 56 (range 34–77). Again, germline BRCA2 variation predominated, with 8 (8%) testing positive, but only one (less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback